Zobrazeno 1 - 10
of 290
pro vyhledávání: '"Daniel L. Gillen"'
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-5 (2023)
Abstract Background Participant retention is a key factor that affects clinical trial integrity. Trial protocols estimate attrition as a function of sample size calculations. Alzheimer’s disease (AD) is an area of active treatment development. We a
Externí odkaz:
https://doaj.org/article/5b04dc8699cd45708b4b9f8fbdb8e3fa
Autor:
Roy S. Zawadzki, Joshua D. Grill, Daniel L. Gillen, and for the Alzheimer’s Disease Neuroimaging Initiative
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-24 (2023)
Abstract To estimate causal effects, analysts performing observational studies in health settings utilize several strategies to mitigate bias due to confounding by indication. There are two broad classes of approaches for these purposes: use of confo
Externí odkaz:
https://doaj.org/article/6296f20c76b24a2faa1cd455fc92da91
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 4, Pp n/a-n/a (2023)
Abstract INTRODUCTION Alzheimer's disease (AD) trials require enrollment with an informant. METHODS We assessed relationships between informant replacement and Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS‐ADL) scores acros
Externí odkaz:
https://doaj.org/article/7959d1c5396148068726c7d63efad7eb
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-9 (2023)
Abstract Background Timely accrual of a representative sample is a key factor in whether Alzheimer’s disease (AD) clinical trials successfully answer the scientific questions under study. Studies in other fields have observed that, over time, recru
Externí odkaz:
https://doaj.org/article/afdf4e1a55b540678d277b7fe1b8fdad
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 8, Pp 1646-1655 (2021)
Abstract Objectives Preclinical Alzheimer’s disease (AD) clinical trials screen cognitively unimpaired older adults for biomarker criteria and disclose their results. We examined whether participants in the Anti‐Amyloid Treatment in Asymptomatic
Externí odkaz:
https://doaj.org/article/972d22bd0bdb49c3a8dfdf6ebd874ae0
Publikováno v:
BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-15 (2021)
Abstract Background Various interacting and interdependent components comprise complex interventions. These components create difficulty in assessing the true impact of interventions designed to improve patient-centered outcomes. Interrupted time ser
Externí odkaz:
https://doaj.org/article/6cf4781eec2f4d6a9b9833ba785c748a
Autor:
Nicholas J. Tustison, Philip A. Cook, Andrew J. Holbrook, Hans J. Johnson, John Muschelli, Gabriel A. Devenyi, Jeffrey T. Duda, Sandhitsu R. Das, Nicholas C. Cullen, Daniel L. Gillen, Michael A. Yassa, James R. Stone, James C. Gee, Brian B. Avants
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract The Advanced Normalizations Tools ecosystem, known as ANTsX, consists of multiple open-source software libraries which house top-performing algorithms used worldwide by scientific and research communities for processing and analyzing biologi
Externí odkaz:
https://doaj.org/article/8a730c2b91564fcbbff35342a39fe8ae
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-11 (2021)
Abstract Background Early study exit is detrimental to statistical power and increases the risk for bias in Alzheimer’s disease clinical trials. Previous analyses in early phase academic trials demonstrated associations between rates of trial incom
Externí odkaz:
https://doaj.org/article/dce1d94b7879423c883c4648314c48dd
Autor:
Michelle M. Nuño, Daniel L. Gillen, Joshua D. Grill, for the Alzheimer’s Disease Cooperative Study
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-7 (2019)
Abstract Background Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose role includes assessing participant cognitive and functional performance. AD trials now investigate early stages of the dise
Externí odkaz:
https://doaj.org/article/4f9a50e6b8f74e5c9ab51d70d8746ad1
Autor:
Mary M. Ryan, Joshua D. Grill, Daniel L. Gillen, for the Alzheimer’s Disease Neuroimaging Initiative
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-8 (2019)
Abstract Background Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study partners, compar
Externí odkaz:
https://doaj.org/article/1cea0af117a94ed29a17c06a3046598d